The starting point is a well-documented misalignment between what researchers study and what factories need. The most consequential industrial problems, from equipment failures and quality defects to supply chain disruptions, safety incidents and energy waste, are often distributed across departments, so that the true cost of any one of them is invisible to any single unit. Established identification methods struggle with exactly this property. Failure Mode and Effects Analysis, the dominant structured technique in manufacturing, relies on multi-day workshops with expensive cross-functional participation. Lean audits and consultancy engagements share the same weaknesses: they are episodic, dependent on the knowledge of whoever happens to be in the room, and organised along departmental lines. The authors distil four recurring limitations of these approaches, describing them as episodic, expertise-dependent, siloed and qualitatively biased.

The proposed alternative is a conceptual framework in which six domain-specialised agents, covering production, quality, maintenance, supply chain, safety and energy, collaborate through a five-phase protocol. The architecture has three layers: a human interface layer where workers interact with the agents, a collaboration layer where agents communicate through structured protocols on a publish-subscribe message bus, and an output layer producing prioritised problem rankings, a financial impact report and a register of safety-critical items. Each agent would combine a domain-specific system prompt encoding standards such as ISO 55000 for maintenance or ISO 50001 for energy, structured interview templates, short-term working memory, a persistent knowledge base and an interface to the message bus. The authors describe the overall concept as a cognitive organisational twin, a software mirror of the firm’s knowledge structure updated by conversation rather than by telemetry, in deliberate contrast to the digital twin that mirrors physical assets.

The five-phase protocol begins with worker-driven discovery, in which each agent conducts structured interviews within its own department and converts unstructured testimony into standardised problem records containing severity, frequency, estimated financial impact, affected performance indicators, suspected root causes and current workarounds. In the second phase, every discovered problem is broadcast to all agents, each of which scores its relevance to its own domain, assigns an independent severity assessment and flags financial impacts invisible to the originating department. The third phase searches for relationships between problems, distinguishing candidate common causes, candidate causal influences and reported co-occurrences, with the authors insisting that every such link remains a hypothesis for human verification rather than a detected causal relationship. The fourth phase produces consensus-based financial estimates, and the fifth aggregates the agents’ ranked preferences through debate.

What distinguishes the paper from many AI framework proposals is the mathematical specificity of its prioritisation procedure. Agent financial estimates, normalised to expected annualised cost over a twelve-month horizon, are combined by taking the median across the six agents, with an interquartile dispersion ratio used to attach confidence labels: values of 0.25 or below are labelled consistent, up to 0.75 dispersed, and above 0.75 unreliable. Criteria weights are elicited from plant management through the analytic hierarchy process, and the resulting decision matrix is scored by TOPSIS, a standard multi-criteria method, while the agents’ holistic rankings are aggregated by a normalised Borda count. The two components are blended in a combined score whose weighting parameter must be explicitly reported along with a sensitivity analysis. Notably, the framework refuses to compute the familiar FMEA Risk Priority Number, because multiplying ordinal severity, occurrence and detection scores as though they were ratio quantities is precisely the defect the authors identify in the traditional method.

Two safeguards anchor the design. The first is a non-compensatory safety gate: if any of the six severity assessments assigns a score of eight or more, corresponding to potential fatality, permanent injury or major loss of containment, the problem is placed on a mandatory review register and referred for expert safety assessment regardless of where it ranks. The need for this gate emerges starkly from the authors’ worked calculation. In their hypothetical example, a combustible dust hazard with the highest possible severity is ranked only third by the compensatory scoring system, because its rarity drives down its expected annual cost and allows recurring losses to offset it. The financial figure responsible for pushing the hazard down is also the one the procedure itself labels unreliable. The second safeguard is a mandatory human verification gate: no output of the system is a decision, every financial figure must be re-estimated by a human from company data, and any causal claim must be checked against process or maintenance records before action follows.

Because the entire input to the framework comes from conversations between workers and agents, the authors devote unusual attention to the ethics of that interaction. They specify six design requirements: voluntary participation with an unconditional opt-out, no individual attribution in any record, non-punitive use of the data, operation in the languages actually spoken on the shopfloor, access to a human facilitator who is not part of line management, and provenance labels distinguishing what a worker reported from what a model inferred or what was retrieved from company documents. In several European jurisdictions, consultation with employee representation before deployment is a legal precondition. Whether workers will actually speak candidly to such a system, given concerns about job security and prior experience of monitoring technology, is treated as an open empirical question rather than an assumption.

The authors are equally candid about the limits of their own proposal. The most consequential weakness is that six agents built on one base model do not constitute six independent estimators: their errors are correlated by construction, so agreement among them should be read as consistency, never as corroboration. Financial estimates produced by language models are uncalibrated, and no study identified in the review grounds such estimates against realised industrial costs. Hallucination poses a specific hazard here, since a fabricated problem record would be indistinguishable in style from a genuine one, and long-term knowledge bases can propagate and entrench errors. A systematic review cited in the paper, which screened 2341 publications on foundation-model agents in industrial automation, found most systems at technology readiness levels four to six, with genuine deployments in only about nine per cent of cases, and recurring barriers including generalisation failure, hallucination and output instability.

Perhaps the most striking feature of the article is its own worked example turning against the concept it illustrates. In a hypothetical vignette of a Nordic steel plant with 450 employees, the agents would surface a recurring crusher bearing failure, unrecovered furnace heat and an accumulating combustible dust hazard, and would hypothesise a common cause in deferred capital investment, exactly the kind of cross-departmental insight a single-department assessment would miss. Yet the final ranking places the catastrophic hazard third, below routine losses, and only the safety gate and the dispersion label catch it. The authors present this outcome as a property of compensatory aggregation rather than of the chosen figures, and they conclude that the framework’s most honest claim is a negative one: the first question on their fourteen-question research agenda is whether six agents achieve anything a single agent, or a well-run workshop, does not. Until that is answered, the proposal stands as a precisely stated hypothesis about organising AI at the industry-academia interface, one explicit enough to be refuted.

Subject of Research: Large language model multiagent systems for discovering and prioritising industrial manufacturing problems

Article Title: Large language model multiagent systems for industrial problem discovery and prioritization

Article References: Adoul, M. A., & Ghoul, A. (2026). Large language model multiagent systems for industrial problem discovery and prioritization. Discover Artificial Intelligence, 6(1), Article 1456. https://doi.org/10.1007/s44163-026-02468-6

Image Credits: AI Generated

DOI: 10.1007/s44163-026-02468-6

Keywords: large language models, multiagent systems, manufacturing, FMEA, industrial problem discovery, prioritisation, TOPSIS, Borda count, Industry 5.0, human-AI collaboration, safety gate, cognitive twin

The argument emerges from a growing mismatch between the architecture of medical evidence and the reality of modern patients. Clinical guidelines are overwhelmingly built for single diseases: one condition, one evidence base, one optimised pathway. But the patients walking into general practice and general internal medicine increasingly carry several long-term conditions at once, often bridging physical and mental health, cardiovascular risk, chronic pain, frailty, and social vulnerability. Large analyses of electronic health records show that multimorbidity clusters into recurring patterns that cut across these domains, and that the condition is associated with poorer function, worse quality of life, higher healthcare use, and earlier onset in deprived communities. For such a patient, the clinical problem is not only disease burden but healthcare burden: the appointments, tests, self-monitoring, medications, side effects, and contradictory advice that accumulate when each disease is managed by its own logic.

Consider a patient with type 2 diabetes, osteoarthritis, depression, hypertension, insomnia, and chronic kidney disease. The generalist seeing this person is not simply applying six evidence bases in sequence. The authors argue that the clinician is reconciling six partially incompatible logics of care, each with its own targets, monitoring schedules, and pharmacological demands. A diabetes guideline may push tight glycaemic control; the kidney disease may complicate the drugs used to achieve it; the depression may undermine the self-management every other condition depends on; the osteoarthritis may make exercise, the universal recommendation, painful. The question that actually matters in the consultation is not what each guideline advises, but what the next best thing to do for this person now happens to be.

That question becomes urgent when the mathematics of prevention is examined honestly. Modelling work cited in the Perspective shows that ignoring competing mortality can substantially overestimate the expected benefit of preventive interventions in older adults and people with multimorbidity. A statin, a blood pressure tablet, or a screening test may offer a genuine relative risk reduction, but if the competing risks of age, frailty, and other diseases intervene first, the absolute benefit shrinks, while the burden of taking the treatment remains fully present. The authors also highlight direct treatment disutility, the harm and inconvenience a treatment imposes in its own right, which can flip the balance between benefit and harm. Evidence, in other words, does not speak for itself; it must be adjudicated against life expectancy, burden, and the patient’s own goals.

And patients, it turns out, often adjudicate differently from their doctors. A systematic mixed-studies review found that patients with multimorbidity commonly prioritise symptom relief and the preservation of function and independence, whereas clinicians tend to prioritise longer-term risk reduction and surrogate markers. This divergence is not a failure of communication to be corrected but a structural feature of complex care that must be made visible. The Perspective is careful to distinguish prioritisation from its neighbouring concepts: it is not shared decision-making, though shared decision-making safeguards it; not deprescribing, though deprescribing is one of its tools; not treatment burden measurement, though burden is one of its inputs; and not Choosing Wisely, though it extends that movement’s logic. Its distinctive work is deciding what should come first now, what can wait, and what should stop.

Crucially, the authors insist that generalists already perform this work, but implicitly and without a language that grants it legitimacy. Qualitative studies of physicians caring for complex patients show that their decisions are shaped by disease interactions, patient resources, consultation constraints, organisational pressures, continuity of relationship, and the effort to steer care toward a workable goal. Physicians report that patient values matter, yet are not always elicited directly and are difficult to reconcile with protocols, multidisciplinary teams, and families. Even committed clinicians describe limited time and systems that reward the completion of checklists far more readily than the exercise of judgment. The result is a paradox the authors name directly: prioritisation is central to good generalist care, yet it remains under-described, under-taught, and under-valued.

The Perspective does not leave the concept abstract. It points to a growing body of implementation research that moves goal-oriented care from theory toward operational reality. Grudniewicz and colleagues have proposed strengthening the Chronic Care Model by subordinating disease management to what matters most to the person over time, rather than abandoning disease management altogether. Tinetti and colleagues tested a patient priorities-aligned care model for older adults with multiple conditions and reported potentially favourable differences in treatment burden and shared prescribing decisions compared with usual care, although the differences did not reach statistical significance. Schuttner and colleagues used multicriteria decision analysis to demonstrate something clinically profound: the right next step changes depending on whether the patient’s aim is mortality reduction, symptom relief, or preserved function. Prioritisation, in other words, is not a fixed ranking but a dynamic computation that depends on the goal.

Making prioritisation explicit, the authors argue, requires deliberate elicitation of what matters now. They describe a simple clinical sequence: identify what matters most to the patient at this moment, select the next action with the greatest likely benefit and lowest burden relative to that goal, and actively stop, simplify, or defer care that does not serve it. Supporting tools are emerging. Person-centred care approaches built around extended consultations, personalised goal setting, and planned follow-up have been developed in general practice, and one research group has even produced a prioritisation algorithm to identify which patients are most likely to benefit from a longer, goal-setting appointment in time-constrained settings. Communication and goal-setting tools such as structured wellbeing journals have shown promise in supporting more meaningful care-planning conversations with older adults. The lesson, the authors stress, is not that every consultation must become long or formalised, but that a good consultation may sometimes be one in which fewer targets are addressed and the patient leaves with a clearer plan, lower burden, and fewer contradictory demands.

The hardest test of prioritisation is whether it leads to de-intensification. Adding treatment is easy to justify, because each addition can be defended by a disease-specific rationale; stopping requires accepting responsibility for uncertainty. Yet the authors argue that prioritisation which never results in stopping is performative rather than real. The evidence here is genuinely mixed, and they are candid about it. Deprescribing interventions generally reduce medication counts, and a meta-analysis found benefits on potentially inappropriate prescribing and adverse drug reactions in older adults, but evidence for broader outcomes remains inconsistent, particularly in vulnerable multimorbid populations. Structured medication reviews, meanwhile, are hampered by time pressure, organisational complexity, unclear roles, and poor data integration, according to qualitative findings from the DynAIRx study. This is the landscape in which generalists operate: enough evidence to justify action, never enough to eliminate judgment.

The Perspective closes with a warning about how the SPPiRE analysis complicates even well-intentioned priority elicitation: when general practitioners prioritised pain, opioid intensification became more likely despite guideline concerns about chronic pain pharmacotherapy in older adults. Eliciting priorities, the authors conclude, is necessary but not sufficient; priorities must still be interpreted through a generalist lens weighing immediate suffering against long-term harm. The wider implications reach into education, where trainees should learn to justify not only what they do but what they decline to do; into quality measurement, which should reward goal-concordant sequencing and burden reduction rather than indiscriminate completion; and into system design, where altered specialist treatments should be documented and reconciled so that patients are not left as messengers between competing experts. In complexity, the authors write, the central clinical task is deciding what deserves attention first, what can wait, and what no longer serves the patient. Prioritisation, they argue, is the treatment decision.

Subject of Research: Prioritisation as a clinical intervention in generalist care for patients with multimorbidity

Article Title: Prioritisation Is Treatment: What Generalists Do When Guidelines Collide

Article References: Jerjes, W., & Majeed, A. (2026). Prioritisation Is Treatment: What Generalists Do When Guidelines Collide. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10861-1

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10861-1

Keywords: generalism, multimorbidity, prioritisation, clinical guidelines, polypharmacy, deprescribing, treatment burden, shared decision-making, goal-oriented care, primary care, Choosing Wisely, patient priorities

The biological logic behind the approach rests on a concept called synthetic lethality. When a tumour cell loses the function of one gene, it can often survive because a closely related paralog compensates for the loss. Knock out both genes simultaneously, however, and the cell dies, while normal cells that retain functional copies of both genes remain unharmed. This therapeutic window has already produced clinical successes, most famously the PARP inhibitors used against BRCA-deficient breast and ovarian cancers. Yet the authors of the new study argue that the field’s dominant discovery tool, genome-wide CRISPR screening, is structurally blind to many of these interactions. Standard dependency maps, such as the widely used Cancer Dependency Map, largely capture single-gene effects. When two paralogs back each other up, knocking out either one alone produces no detectable fitness defect, and the underlying dependency goes unnoticed.

Combinatorial CRISPR screens, in which genes are knocked out in pairs, can reveal these masked dependencies, but they are expensive, labour-intensive and therefore limited in scale. More importantly, the paralog synthetic lethal effects they uncover are highly context-dependent, varying across tumour types and genetic backgrounds. A paralog pair that is jointly essential in HER2-amplified breast cancer may be entirely dispensable in lung cancer, and vice versa. To translate paralog synthetic lethality into clinical practice, researchers need to know not just which pairs are synthetic lethal in principle, but which pairs constitute actionable vulnerabilities in which specific cancer settings. That is the gap the Dublin-led team set out to close.

The researchers, led by Narod Daldal and corresponding author Colm J. Ryan, with contributions from Hamda B. Ajmal and David J. Adams, developed a machine learning classifier trained to predict cell-line-specific synthetic lethality between paralog pairs. Rather than relying on a single data type, the model integrates features drawn from transcriptomics, genomics, gene essentiality profiles and protein-protein interaction network context. The intuition is straightforward: if two paralogs are expressed at different levels in a given cell line, if one of them already shows partial essentiality, or if their interaction partners within the cellular network suggest functional compensation, the probability that the pair is synthetic lethal in that specific context changes accordingly. The classifier learns these patterns from pairs where combinatorial screening data already exists and applies them to pairs that have never been tested.

A central methodological strength of the study lies in its evaluation framework, which was deliberately designed to test generalisation across three biologically distinct scenarios. The first asks whether the model can predict synthetic lethality for paralog pairs it has seen before, but in cell lines it has never encountered. The second asks whether it can generalise to entirely unseen paralog pairs within cell lines it knows. The third, and hardest, asks whether it can make predictions for unseen pairs in unseen cell lines. This graduated testing matters because a model that merely memorises known pairs would be of little use for discovery, whereas a model that generalises to novel combinations can genuinely guide new experiments. The results showed that the model generalised to both unseen pairs and unseen cell lines, although the combination of both unknowns remained the most challenging scenario, as expected.

Underpinning the predictions is a finding about which signals carry the most information. The cell-line-specific expression levels and essentiality profiles of the paralogs themselves, and of their interaction partners, proved to be the most informative features for predicting synthetic lethal interactions. In other words, the model does not simply ask whether two genes are related; it asks whether, in a particular tumour cell, the pattern of activity across the paralog pair and its network neighbourhood is consistent with compensatory redundancy. This context sensitivity is precisely what single-gene dependency maps lack, and it is what allows the resulting resource to be stratified by disease subtype and biomarker status.

To assess how well the predictions held up, the team applied the model to 33,419 paralog pairs across 1,005 cancer cell lines and compared its output against independent combinatorial CRISPR screening data. One of the most striking conclusions from this validation is a sobering one for the field: the agreement between predicted and experimentally observed interactions was comparable to the agreement observed between independent experimental studies of the same pairs. This suggests that the ceiling on predictive accuracy may be set as much by the reproducibility of the experiments themselves as by the performance of the model. In a discipline where different laboratories screening the same gene pairs can reach different conclusions, a computational predictor that matches the level of inter-experimental consistency is performing at a biologically meaningful standard, and the authors suggest that improving experimental reproducibility and model accuracy will need to advance together.

The practical value of the framework is illustrated through its application to HER2-amplified breast cancer, a clinically defined subtype driven by amplification of the ERBB2 receptor gene. When restricted to this context, the model successfully recovered known synergistic paralog relationships already documented in the literature, providing an internal check on its reliability. More importantly, it also predicted novel biomarker-associated vulnerabilities that had not previously been experimentally characterised, generating a ranked list of candidate paralog targets specific to this tumour type. Each such prediction represents a hypothesis that can be prioritised for targeted combinatorial screening, dramatically narrowing the search space that would otherwise need to be explored experimentally.

To make the resource usable by the wider research community, the team has released all genome-scale predictions through an interactive web portal, available at cancergenetics.github.io/paralogmap. The portal allows researchers to query specific paralog pairs, filter by cancer type or cell line, and identify context-specific dependencies relevant to their disease of interest. The authors position the resource as a tool for hypothesis generation, for guiding targeted combinatorial screening campaigns, and for facilitating the identification of clinically actionable paralog targets. Because the underlying article is open access, the full dataset and predictions are available without restriction, lowering the barrier for laboratories that lack the computational infrastructure to build such models themselves.

The broader significance of the work lies in what it says about the next generation of precision oncology. Single-gene targets are finite, and many of the most obvious dependencies have already been mapped. Combination strategies aimed at synthetic lethal pairs multiply the therapeutic search space enormously, but only a systematic, context-aware prioritisation framework can make that space tractable. By combining machine learning with the rich molecular profiles now available for hundreds of cancer models, and by validating against the gold standard of combinatorial CRISPR screening, this study offers a template for how hidden, context-specific vulnerabilities can be surfaced at scale. If the predicted vulnerabilities withstand experimental follow-up, paralog pairs could become a rich source of biomarker-guided combination therapies, extending the synthetic lethality paradigm beyond its current clinical footholds and into tumour types where redundant gene pairs have so far kept their weaknesses safely out of sight.

Subject of Research: Machine learning prediction of context-specific paralog synthetic lethal vulnerabilities in cancer

Article Title: Systematic prioritisation of context-specific paralog pair vulnerabilities in cancer

Article References: Daldal, N., Ajmal, H. B., Adams, D. J., & Ryan, C. J. (2026). Systematic prioritisation of context-specific paralog pair vulnerabilities in cancer. Genome Medicine. https://doi.org/10.1186/s13073-026-01759-y

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01759-y

Keywords: paralogs, synthetic lethality, precision oncology, machine learning, CRISPR screening, genetic dependencies, cancer cell lines, HER2-amplified breast cancer, dependency map, Genome Medicine, Systematic, prioritisation